A Phase I, Randomized, Open-Label, Single-Dose, Crossover Study to Evaluate Food Effect on the Pharmacokinetics and Safety of CT-L01 After Oral Administration in Healthy Volunteers
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Alogliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Celltrion
Most Recent Events
- 31 Aug 2022 Status changed from not yet recruiting to completed.
- 16 May 2022 New trial record
- 10 May 2022 Planned End Date changed from 5 Aug 2022 to 29 Jul 2022.